Phathom Pharmaceuticals (PHAT) Non-Current Deffered Revenue (2022 - 2026)

Phathom Pharmaceuticals (PHAT) has reported Non-Current Deffered Revenue for 5 consecutive years, with $347.6 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Non-Current Deffered Revenue changed 0.18% year-over-year to $347.6 million; the TTM figure through Jun 2026 stood at $347.6 million (changed 0.18% YoY), while the FY2025 annual figure was $350.1 million, up 5.06% from the prior year.
• Non-Current Deffered Revenue held at $347.6 million in Q2 2026 per PHAT's latest filing, from $347.9 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $350.1 million in Q4 2025 and bottomed at $109.5 million in Q4 2022.
• Historically, Non-Current Deffered Revenue has averaged $287.0 million across 5 years, with a median of $327.8 million in 2024.
• Annual changes were most pronounced in 2023 — Non-Current Deffered Revenue soared 173.74% — and 2026, when it advanced 0.18%.
• Phathom Pharmaceuticals' Non-Current Deffered Revenue stood at $109.5 million in 2022, then surged by 173.74% to $299.8 million in 2023, then climbed by 11.16% to $333.3 million in 2024, then rose by 5.06% to $350.1 million in 2025, then slipped by 0.71% to $347.6 million in 2026.
• Business Quant data shows PHAT's Non-Current Deffered Revenue at $347.6 million in Q2 2026, $347.9 million in Q1 2026, and $350.1 million in Q4 2025.